NKTR vs. PRGO, SUPN, PCRX, OMER, ASMB, CPIX, LLY, JNJ, ABBV, and MRK
Should you be buying Nektar Therapeutics stock or one of its competitors? The main competitors of Nektar Therapeutics include Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co., Inc. (MRK). These companies are all part of the "pharmaceuticals" industry.
Nektar Therapeutics vs. Its Competitors
Perrigo (NYSE:PRGO) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.
Perrigo has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500.
Nektar Therapeutics has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.
Perrigo currently has a consensus target price of $33.00, suggesting a potential upside of 53.92%. Nektar Therapeutics has a consensus target price of $88.33, suggesting a potential upside of 55.10%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Perrigo.
In the previous week, Nektar Therapeutics had 5 more articles in the media than Perrigo. MarketBeat recorded 14 mentions for Nektar Therapeutics and 9 mentions for Perrigo. Perrigo's average media sentiment score of 0.89 beat Nektar Therapeutics' score of 0.87 indicating that Perrigo is being referred to more favorably in the media.
Perrigo has a net margin of -1.86% compared to Nektar Therapeutics' net margin of -163.17%. Perrigo's return on equity of 9.09% beat Nektar Therapeutics' return on equity.
95.9% of Perrigo shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 0.7% of Perrigo shares are owned by insiders. Comparatively, 5.3% of Nektar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Nektar Therapeutics beats Perrigo on 9 of the 16 factors compared between the two stocks.
Get Nektar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NKTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nektar Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NKTR) was last updated on 9/19/2025 by MarketBeat.com Staff
Free NKTR Stock Alerts